ID   CRO-AP6
AC   CVCL_1811
SY   CRO-AP/6; AP6
DR   BioSample; SAMN03473463
DR   DSMZ; ACC-650
DR   DSMZCellDive; ACC-650
DR   Wikidata; Q54814510
RX   PubMed=10914556;
CC   Doubling time: 40-50 hours (PubMed=10914556); ~48 hours (DSMZ=ACC-650).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 15,16
ST   D19S433: 15
ST   D21S11: 30
ST   D2S1338: 19,21
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 13,15
ST   FGA: 20,24
ST   Penta D: 9
ST   Penta E: 10,12
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 14,15
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 16
//
RX   PubMed=10914556; DOI=10.1038/sj.leu.2401802;
RA   Carbone A., Cilia A.M., Gloghini A., Capello D., Fassone L., Perin T.,
RA   Rossi D., Canzonieri V., De Paoli P., Vaccher E., Tirelli U.,
RA   Volpe R., Gaidano G.;
RT   "Characterization of a novel HHV-8-positive cell line reveals
RT   implications for the pathogenesis and cell cycle control of primary
RT   effusion lymphoma.";
RL   Leukemia 14:1301-1309(2000).
//